INTEGRATED BIOPHARMA INC
Integrated BioPharma manufactures, distributes, markets and sells vitamins, nutritional supplements and herbal products, serving customers primarily in the United States and Luxembourg. Its Contract Manufacturing segment, operated by Manhattan Drug Company, manufactures vitamins and nutritional supplements for distributors, multilevel marketers and specialized health-care providers. The segment also develops, manufactures and supplies certain nutritional products to Herbalife under development and supply agreements. Other Business Lines includes MDC Warehousing and Distribution, which provides warehousing and fulfillment services, and Chem International, which distributes certain raw materials for DSM Nutritional Products and serves as the company’s holding entity. Integrated BioPharma makes money from contract manufacturing, warehousing and fulfillment services, and raw-material distribution. It is headquartered in Hillside, New Jersey.
No SEC Form 4 filings for $INBP in the last 30 days.
See all $INBP insider activity →INTEGRATED BIOPHARMA INC (INBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE for November 13, 2026 Contact: Dina Masi, CFO Integrated BioPharma, Inc. investors@ibiopharma.com 888.319.6962 Integrated BioPharma Reports Results for its Quarter Ended September 30, 2026 HILLSIDE, NEW JERSEY (November 13, 2026) - Integrated BioPharma,
Integrated BioPharma (INBP) reported a 22% revenue decline to $9.9M, with a $0.7M net loss, compared to a $0.1M net income in the prior-year quarter, according to the company.
Integrated BioPharma reported 3Q 2026 revenue of $9.91M, down 21.9% YoY, with a net loss of $691K compared to a prior-year profit. Decreased sales volumes, especially to Life Extension, and lower margins contributed to the decline. Management expects operations and credit facilities to support working capital through November 2027.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning INBP (INTEGRATED BIOPHARMA INC). Coverage has skewed bearish: 0 bullish, 0 neutral, and 4 bearish.
Recent INBP coverage spans earnings and corporate actions.
The earnings miss and operating loss suggest short-term downside pressure.
The loss and revenue decline suggest negative earnings momentum.
Earnings miss with lower revenue and a shift to loss.
Earnings miss and revenue drop likely pressure the stock lower.
Earnings miss may pressure the stock lower; loss widening suggests cash‑flow concerns.
AlphAI scores every news story that mentions INBP with an AI model for sentiment and relevance, and aggregates insider trades from INTEGRATED BIOPHARMA INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
INTEGRATED BIOPHARMA INC (INBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE for November 13, 2026 Contact: Dina Masi, CFO Integrated BioPharma, Inc. investors@ibiopharma.com 888.319.6962 Integrated BioPharma Reports Results for its Quarter Ended September 30, 2026 HILLSIDE, NEW JERSEY (November 13, 2026) - Integrated BioPharma,
Integrated BioPharma (INBP) reported a 22% revenue decline to $9.9M, with a $0.7M net loss, compared to a $0.1M net income in the prior-year quarter, according to the company.
Integrated BioPharma reported 3Q 2026 revenue of $9.91M, down 21.9% YoY, with a net loss of $691K compared to a prior-year profit. Decreased sales volumes, especially to Life Extension, and lower margins contributed to the decline. Management expects operations and credit facilities to support working capital through November 2027.
Integrated BioPharma, Inc. (INBP) reported a 31% revenue decline to $9.8M for Q2 2026 and a 19% drop to $43.9M for the fiscal year, with net losses of $1.4M and $2.8M, respectively. The company attributed the decrease to reduced revenue from its two largest customers, according to its executives.
INTEGRATED BIOPHARMA INC (INBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE for September 25, 2026 Contact: Dina Masi, CFO Integrated BioPharma, Inc. investors@ibiopharma.com 888.319.6962 Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026 HILLSIDE, NEW JERSEY (September 25, 2026) - Integrate
INTEGRATED BIOPHARMA INC (INBP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.2 3 ex_983424.htm EXHIBIT 10.2 CONVERTIBLE LINE OF CREDIT NOTE ex_983424.htm Exhibit 10.2 Convertible Line of Credit Note (Daily SOFR) $250,000.00 June 30, 2026 FOR VALUE RECEIVED , INTEGRATED BIOPHARMA, INC. , with an address at 225 LONG AVE, STE 15, HILLSIDE, NEW JERSEY 0
